Management of chronic heart failure due to systolic left ventricular dysfunction by cardiologist and non-cardiologist

Sinéad P McKee1, Stephen J Leslie, John P LeMaitre

  • 1Cardiology Unit, Department of Medical Sciences, The University of Edinburgh, Western General Hospital, EH4 2XU, Edinburgh, UK.

Insights

Implementation of chronic heart failure (CHF) guidelines is poor, even in university hospitals. Adherence to evidence-based therapies like beta-blockers and spironolactone is low, impacting patient outcomes and hospital admissions.

Area of Science:

  • Cardiology
  • Clinical Practice Guidelines
  • Health Services Research

Background:

  • Numerous guidelines exist for chronic heart failure (CHF) diagnosis and management.
  • The real-world implementation and impact of these guidelines on patient outcomes remain unclear.

Purpose of the Study:

  • To evaluate the adherence to a specific systolic heart failure guideline (Scottish Intercollegiate Guideline Network, number 35) in a university hospital.
  • To compare guideline adherence between cardiologists and non-cardiologists.
  • To assess the association between guideline adherence and hospital admission rates.

Main Methods:

  • Retrospective analysis of case records from 400 patients with a primary CHF diagnosis.
  • Assessment of management against the Scottish Intercollegiate Guideline Network (SIGN) 35 guideline.
  • Examination of hospital admission data over 17 months.

Main Results:

  • Overall guideline adherence was poor, with high use of ACE inhibitors/ARBs (80%) but low use of beta-blockers (32%) and spironolactone (13%).
  • Cardiologists demonstrated higher use of beta-blockers and digoxin in sinus rhythm compared to non-cardiologists.
  • Increased hospital admissions were associated with age, NYHA status, and higher diuretic prescription, but not overall guideline adherence in multivariable analysis.

Conclusions:

  • Evidence-based therapies for CHF are inadequately implemented, even in academic settings.
  • Lack of organizational support may hinder complex CHF patient management.
  • Further research into barriers and facilitators of guideline implementation is warranted.

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...